CancerVax
Updated: April 01, 2026
CEO - Byron Elton
Country: USA | Funding: $146.5M (+)
Founded: 1993
Website: https://www.cancervax.com
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
Founded: 1993
Website: https://www.cancervax.com
CancerVax is developing a new bispecific antibody vaccine for the treatment of recurrent Ewing sarcoma. This therapeutic vaccine can target and attach to Ewing sarcoma cancer cells, recruiting the body's natural killer T cells to the tumor to destroy it; hence the name "bispecific." In extensive laboratory cell studies, several candidates demonstrated significant T-cell killing of Ewing sarcoma cells, meaning the vaccine was doing its job of recruiting T cells to the tumor cells for destruction. The company also has candidates for the treatment of pancreatic and liver cancer.
